These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 30773463)

  • 21. Lipase-triggered drug release from BCL2 inhibitor ABT-199-loaded nanoparticles to elevate anti-leukemic activity through enhanced drug targeting on the mitochondrial membrane.
    Liang B; Jiang D; Pan L; Xiong F; Feng S; Wu S; Ye H; Yu Z; Shi C; Gao S
    Acta Biomater; 2022 Jun; 145():246-259. PubMed ID: 35405327
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pairing MCL-1 inhibition with venetoclax improves therapeutic efficiency of BH3-mimetics in AML.
    Hormi M; Birsen R; Belhadj M; Huynh T; Cantero Aguilar L; Grignano E; Haddaoui L; Guillonneau F; Mayeux P; Hunault M; Tamburini J; Kosmider O; Fontenay M; Bouscary D; Chapuis N
    Eur J Haematol; 2020 Nov; 105(5):588-596. PubMed ID: 32659848
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Deregulation of the mitochondrial apoptotic machinery and development of molecular targeted drugs in acute myeloid leukemia.
    Del Poeta G; Bruno A; Del Principe MI; Venditti A; Maurillo L; Buccisano F; Stasi R; Neri B; Luciano F; Siniscalchi A; de Fabritiis P; Amadori S
    Curr Cancer Drug Targets; 2008 May; 8(3):207-22. PubMed ID: 18473734
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mitochondrial Reprogramming Underlies Resistance to BCL-2 Inhibition in Lymphoid Malignancies.
    Guièze R; Liu VM; Rosebrock D; Jourdain AA; Hernández-Sánchez M; Martinez Zurita A; Sun J; Ten Hacken E; Baranowski K; Thompson PA; Heo JM; Cartun Z; Aygün O; Iorgulescu JB; Zhang W; Notarangelo G; Livitz D; Li S; Davids MS; Biran A; Fernandes SM; Brown JR; Lako A; Ciantra ZB; Lawlor MA; Keskin DB; Udeshi ND; Wierda WG; Livak KJ; Letai AG; Neuberg D; Harper JW; Carr SA; Piccioni F; Ott CJ; Leshchiner I; Johannessen CM; Doench J; Mootha VK; Getz G; Wu CJ
    Cancer Cell; 2019 Oct; 36(4):369-384.e13. PubMed ID: 31543463
    [TBL] [Abstract][Full Text] [Related]  

  • 25. NOXA-mediated degradation of MCL1 and BCL2L1 causes apoptosis of daunorubicin-treated human acute myeloid leukemia cells.
    Chiou JT; Huang NC; Huang CH; Wang LJ; Lee YC; Shi YJ; Chang LS
    J Cell Physiol; 2021 Nov; 236(11):7356-7375. PubMed ID: 33982799
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Inhibition of Mcl-1 with the pan-Bcl-2 family inhibitor (-)BI97D6 overcomes ABT-737 resistance in acute myeloid leukemia.
    Pan R; Ruvolo VR; Wei J; Konopleva M; Reed JC; Pellecchia M; Andreeff M; Ruvolo PP
    Blood; 2015 Jul; 126(3):363-72. PubMed ID: 26045609
    [TBL] [Abstract][Full Text] [Related]  

  • 27. BH3 Inhibitor Sensitivity and Bcl-2 Dependence in Primary Acute Lymphoblastic Leukemia Cells.
    Alford SE; Kothari A; Loeff FC; Eichhorn JM; Sakurikar N; Goselink HM; Saylors RL; Jedema I; Falkenburg JH; Chambers TC
    Cancer Res; 2015 Apr; 75(7):1366-75. PubMed ID: 25649768
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Shutting Down Acute Myeloid Leukemia and Myelodysplastic Syndrome with BCL-2 Family Protein Inhibition.
    Sharma P; Pollyea DA
    Curr Hematol Malig Rep; 2018 Aug; 13(4):256-264. PubMed ID: 29982865
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Reduced Mitochondrial Apoptotic Priming Drives Resistance to BH3 Mimetics in Acute Myeloid Leukemia.
    Bhatt S; Pioso MS; Olesinski EA; Yilma B; Ryan JA; Mashaka T; Leutz B; Adamia S; Zhu H; Kuang Y; Mogili A; Louissaint A; Bohl SR; Kim AS; Mehta AK; Sanghavi S; Wang Y; Morris E; Halilovic E; Paweletz CP; Weinstock DM; Garcia JS; Letai A
    Cancer Cell; 2020 Dec; 38(6):872-890.e6. PubMed ID: 33217342
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mitochondrial Profiling of Acute Myeloid Leukemia in the Assessment of Response to Apoptosis Modulating Drugs.
    Ishizawa J; Kojima K; McQueen T; Ruvolo V; Chachad D; Nogueras-Gonzalez GM; Huang X; Pierceall WE; Dettman EJ; Cardone MH; Shacham S; Konopleva M; Andreeff M
    PLoS One; 2015; 10(9):e0138377. PubMed ID: 26375587
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Matrine induces apoptosis in human acute myeloid leukemia cells via the mitochondrial pathway and Akt inactivation.
    Zhang S; Zhang Y; Zhuang Y; Wang J; Ye J; Zhang S; Wu J; Yu K; Han Y
    PLoS One; 2012; 7(10):e46853. PubMed ID: 23056487
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Binding of Released Bim to Mcl-1 is a Mechanism of Intrinsic Resistance to ABT-199 which can be Overcome by Combination with Daunorubicin or Cytarabine in AML Cells.
    Niu X; Zhao J; Ma J; Xie C; Edwards H; Wang G; Caldwell JT; Xiang S; Zhang X; Chu R; Wang ZJ; Lin H; Taub JW; Ge Y
    Clin Cancer Res; 2016 Sep; 22(17):4440-51. PubMed ID: 27103402
    [TBL] [Abstract][Full Text] [Related]  

  • 33. JAK1/2 and BCL2 inhibitors synergize to counteract bone marrow stromal cell-induced protection of AML.
    Karjalainen R; Pemovska T; Popa M; Liu M; Javarappa KK; Majumder MM; Yadav B; Tamborero D; Tang J; Bychkov D; Kontro M; Parsons A; Suvela M; Mayoral Safont M; Porkka K; Aittokallio T; Kallioniemi O; McCormack E; Gjertsen BT; Wennerberg K; Knowles J; Heckman CA
    Blood; 2017 Aug; 130(6):789-802. PubMed ID: 28619982
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Synthetic Lethality of Combined Bcl-2 Inhibition and p53 Activation in AML: Mechanisms and Superior Antileukemic Efficacy.
    Pan R; Ruvolo V; Mu H; Leverson JD; Nichols G; Reed JC; Konopleva M; Andreeff M
    Cancer Cell; 2017 Dec; 32(6):748-760.e6. PubMed ID: 29232553
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Inhibition of Bcl-2 Synergistically Enhances the Antileukemic Activity of Midostaurin and Gilteritinib in Preclinical Models of FLT3-Mutated Acute Myeloid Leukemia.
    Ma J; Zhao S; Qiao X; Knight T; Edwards H; Polin L; Kushner J; Dzinic SH; White K; Wang G; Zhao L; Lin H; Wang Y; Taub JW; Ge Y
    Clin Cancer Res; 2019 Nov; 25(22):6815-6826. PubMed ID: 31320594
    [TBL] [Abstract][Full Text] [Related]  

  • 36. HOX gene expression predicts response to BCL-2 inhibition in acute myeloid leukemia.
    Kontro M; Kumar A; Majumder MM; Eldfors S; Parsons A; Pemovska T; Saarela J; Yadav B; Malani D; Fløisand Y; Höglund M; Remes K; Gjertsen BT; Kallioniemi O; Wennerberg K; Heckman CA; Porkka K
    Leukemia; 2017 Feb; 31(2):301-309. PubMed ID: 27499136
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Embelin potentiates venetoclax-induced apoptosis in acute myeloid leukemia cells.
    Reis-Silva CSM; Branco PC; Lima K; Silva FL; Moreno PRH; Guallar V; Costa-Lotufo LV; Machado-Neto JA
    Toxicol In Vitro; 2021 Oct; 76():105207. PubMed ID: 34216723
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The Bcl-2 inhibitor venetoclax inhibits Nrf2 antioxidant pathway activation induced by hypomethylating agents in AML.
    Nguyen LXT; Troadec E; Kalvala A; Kumar B; Hoang DH; Viola D; Zhang B; Nguyen DQ; Aldoss I; Ghoda L; Budde E; Pichiorri F; Rosen S; Forman SJ; Marcucci G; Pullarkat V
    J Cell Physiol; 2019 Aug; 234(8):14040-14049. PubMed ID: 30623427
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Synergistic AML Cell Death Induction by Marine Cytotoxin (+)-1(
    Florean C; Kim KR; Schnekenburger M; Kim HJ; Moriou C; Debitus C; Dicato M; Al-Mourabit A; Han BW; Diederich M
    Mar Drugs; 2018 Dec; 16(12):. PubMed ID: 30572618
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Concomitant inhibition of MDM2 and Bcl-2 protein function synergistically induce mitochondrial apoptosis in AML.
    Kojima K; Konopleva M; Samudio IJ; Schober WD; Bornmann WG; Andreeff M
    Cell Cycle; 2006 Dec; 5(23):2778-86. PubMed ID: 17172851
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.